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Abstract
Objective The alpha 7 nicotinic receptor (a7nAChR) is
expressed by oral keratinocytes. a7nAChR activation
mediates anti-inflammatory responses. The objective of
this study was to determine if a7nAChR activation inhib-
ited pathogen-induced interleukin-8 (IL-8) expression by
oral keratinocytes.
Materials and methods Periodontal tissue expression of
a7nAChR was determined by real-time PCR. OKF6/
TERT-2 oral keratinocytes were exposed to Porphyro-
monas gingivalis in the presence and absence of a
a7nAChR agonist (PHA-543613 hydrochloride) alone or
after pre-exposure to a specific a7nAChR antagonist (a-
bungarotoxin). Interleukin-8 (IL-8) expression was mea-
sured by ELISA and real-time PCR. Phosphorylation of the
NF-jB p65 subunit was determined using an NF-jB p65
profiler assay and STAT-3 activation by STAT-3 in-cell
ELISA. The release of ACh from oral keratinocytes in
response to P. gingivalis lipopolysaccharide was deter-
mined using a GeneBLAzer M3 CHO-K1-bla cell reporter
assay.
Results Expression of a7nAChR mRNA was elevated in
diseased periodontal tissue. PHA-543613 hydrochloride
inhibited P. gingivalis-induced expression of IL-8 at the
transcriptional level. This effect was abolished when cells
were pre-exposed to a specific a7nAChR antagonist, a-
bungarotoxin. PHA-543613 hydrochloride downregulated
NF-jB signalling through reduced phosphorylation of the
NF-jB p65-subunit. In addition, PHA-543613 hydrochlo-
ride promoted STAT-3 signalling by maintenance of
phosphorylation. Furthermore, oral keratinocytes upregu-
lated ACh release in response to P. gingivalis
lipopolysaccharide.
Conclusion These data suggest that a7nAChR plays a
role in regulating the innate immune responses of oral
keratinocytes.
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Introduction
The alpha 7 nicotinic acetylcholine receptor (a7nAChR)
plays a key role in regulating the ‘cholinergic anti-
inflammatory pathway’ [1–3]. The ‘cholinergic anti-
inflammatory pathway’ is a mechanism by which the
autonomous nervous system can modulate inflammation.
The afferent branch of the vagus nerve relays inflammatory
signals emanating from tissues to the brain. In response,
acetylcholine (ACh) is released via increased efferent vagal
nerve activity. The released ACh then binds to a7AChRs
on proximal immunocompetent cells and downregulates
localised inflammation [4].
Studies using vagotomised animals have shown the
importance of the ‘cholinergic anti-inflammatory pathway’
in regulating inflammatory responses to pathogens. In a
polymicrobial model of abdominal sepsis, vagotomised
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animals showed elevated serum levels of tumour necrosis
factor alpha (TNF-a) and interleukin (IL)-6 [5]. Similarly,
in a mouse model of bacterial lipopolysaccharide (LPS)-
induced endotoxic shock, vagotomised animals demon-
strated increased levels of both serum and hepatic TNF-a
[4]. These studies highlight the functional relevance of the
vagus nerve—immune system cross-talk. However, whe-
ther the apparent anti-inflammatory effects are exclusively
mediated via vagus nerve-derived ACh remains unresolved
[6–8]. Indeed, ex vivo, the anti-inflammatory responses of
cells to cholinergic agonists are mediated by mechanisms
independent of vagus nerve activity [9]. Thus, non-neuro-
nal ACh may also play a role in regulating localised
inflammation at sites far removed from the influence of the
vagus nerve.
Studies using a7nAChR-deficient (a7nAChR-/-) ani-
mals have shown the key role that a7nAChR plays in
regulating the ‘cholinergic anti-inflammatory pathway’.
a7nAChR-/- mice intratracheally instilled with 5 mg/ml
Escherichia coli LPS, or instilled with 107 colony-forming
units (CFU) directly into the lung air spaces, demonstrated
higher mortality from sepsis-induced lung injury and had
more severe lung damage than control a7nAChR?/? ani-
mals [10]. In addition, a7nAChR-/- mice injected
intraperitoneally with LPS were found to be hypersensitive
and presented with increased expression levels of TNF-a in
serum, liver and the spleen as well as increased levels of
IL-1b and IL-6 in serum [11].
a7nAChR is widely expressed by immunocompetent
cells which can also synthesise and release ACh [12].
This therefore suggests that both autocrine and paracrine
mechanisms are in place to regulate inflammation.
In vitro, the pharmacological a7nAChR agonist 3-(2,4-
dimethoxybenzylidene) anabaseine (GTS-21) inhibited
Toll-like receptor (TLR)-mediated expression of TNF-a
and IL-6 from macrophages [13]. Furthermore, activation
of a7nAChR has been shown to reduce IL-8 expression
by epithelial cells of patients with cystic fibrosis [14]
and human colon epithelial cells [15]. In addition,
a7nAChR activation reduced TNF-a expression by
HBE16 airway epithelial cells [16] and reduced expres-
sion of IL-6 and IL-8 from fibroblast-like synoviocytes
[17].
The mechanisms by which a7nAChR mediates anti-
inflammatory responses have been elucidated in monocytes/
macrophages. a7nAChR activation inhibited the transcrip-
tional activity of nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-jB) [18]. In addition, a7nAChR
activation also stimulated the Janus kinase 2/signal trans-
ducer and activator of transcription 3 (JAK-2/STAT-3)
pathway, leading to inhibited pro-inflammatory cytokine
expression, and promoting IL-10 expression [19]. Therefore,
a7nAChR activation can specifically induce downregulated
expression of pro-inflammatory cytokines whilst promoting
expression of anti-inflammatory cytokines.
Periodontal disease is a chronic inflammatory condition
affecting the complex anatomical structures which support
the teeth. Although the primary initiating factor is the
pathogenic microflora of subgingival plaque, periodontal
disease results from an inappropriately excessive and
dysregulated immune response to these bacteria. a7nAChR
is widely expressed by resident and migratory cells found
within the periodontium including oral keratinocytes,
fibroblasts, macrophages, neutrophils, B cells and T cells
[12, 20–24]. In addition, oral epithelial cells have been
demonstrated to express all the components required to
synthesise, release and respond to ACh. Gingival epithelial
cells have been shown to express the ACh synthesising
enzyme, choline acetyltransferase (ChAT) [21], and free
ACh has been detected in oral keratinocyte homogenates,
culture supernatants [25] and gingival tissue samples [26].
Furthermore, there is tentative evidence to suggest that
levels of ACh are up-regulated in inflamed gingival tissue
[26]. These observations provide evidence for a non-neu-
ronal cholinergic mechanism operating within periodontal
tissues. However, the cellular mechanisms which control
the synthesis storage and release of ACh within periodontal
tissues remain unknown.
As the host response plays a prominent role in peri-
odontal disease pathogenesis, host response modulation has
emerged as a valid treatment concept [27]. Therefore,
a7nAChR may be a potential therapeutic target. Previous
studies in monocytes have shown that a7nAChR can
inhibit Porphyromonas gingivalis-induced expression of
pro-inflammatory cytokines, while promoting expression of
anti-inflammatory IL-10 [28]; this suggests that cholinergic
mechanisms operate within the periodontium to regulate
the immune responses initiated by periodontal pathogens.
However, studies in oral keratinocytes have shown that
nicotine, acting via nAChRs, can in fact enhance IL-1b and
P. gingivalis LPS-induced IL-8 release [29]. However, the
relative contributions of specific nAChR subunits (such as
a7nAChR) were not investigated in detail in this study.
In this study we begin to investigate the role that
a7nAChR specifically plays in modulating early immune
responses of oral keratinocytes against periodontal patho-
gens. Oral keratinocytes reside at the gingival sulcus and
respond to bacterial challenge via TLRs. Their activation
engages the transcription factor NF-jB to increase
expression and secretion of cytokines and chemokines, in
particular IL-8 (CXCL8). IL-8 plays a pivotal role in the
recruitment of immune cells to sites of infection in the
periodontium. If this process is not regulated appropriately,
it acts as one of the earliest steps in the pathogenesis of
periodontal disease. The data show for the first time that
specific activation of a7nAChR can modulate the activity
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of both the NF-jB and STAT-3 transcription factors and
negatively regulate P. gingivalis-induced IL-8 expression
by oral keratinocytes. In addition, the release of ACh from
oral keratinocytes is mediated by P. gingivalis LPS. These
findings suggest that complex cholinergic mechanisms
operate within the periodontium. Furthermore, as the oral
mucosa shows structural similarities to mucosal tissues in
the gut, lungs and many other organ systems, it is inter-
esting to speculate that non-neuronal cholinergic
mechanisms may be involved in regulating pathogen-
induced inflammation at other mucosal surfaces.
Materials and methods
RNA isolation from periodontal tissue
Diseased tissues were obtained from patients with peri-
odontal disease undergoing surgery in the Unit of
Periodontics at Glasgow Dental Hospital. Healthy tissues
were taken from patients undergoing non-periodontal dis-
ease-related mucogingival surgery. Ethical review and
approval was provided by the West of Scotland Research
Ethics Committee. Written consent was obtained from all
participants. The tissue samples were immediately sub-
merged in RNAlaterTM (Qiagen, UK) and stored at
-80 C. RNA extraction and purification from tissue
samples was carried out using the RNeasy Fibrous Tissue
Kit (Qiagen).
TaqMan real-time PCR
mRNA was reverse transcribed to cDNA using the High
Capacity RNA-to-cDNA Master Mix (Applied Biosystems,
UK) according to the manufacturer’s instructions. Real-
time PCR was carried out using TaqMan Gene Expres-
sion Master Mix (Applied Biosystems) and TaqMan Gene
Expression Assay Mix for the following genes—
a7nAChR = Hs01063373_m1 and POLR2A (RNA poly-
merase II) = Hs00172187_m1 (both Life Technologies,
UK). Analysis of samples was performed in duplicate in a
96-well plate format on a MX3000PTM real-time PCR
machine (Stratagene, UK). Data were analysed using
MxPro-Mx3000P software, version 4.10 (Stratagene).
Relative expression of a7nAChR mRNA was calculated
using the 2-DCT method [30].
P. gingivalis culture
P. gingivalis biofilms were prepared as follows. P. gingi-
valis ATCC 33277 was cultured at 37 C in Schaedler
anaerobe broth (Oxoid, UK) for 2 days. The bacteria were
then washed by centrifugation in PBS and standardised to
1 9 107 cells/ml in artificial saliva [31]. P. gingivalis (500
ll) suspension was then cultured on Thermanox plastic
coverslips (NUNC, UK) at 37 C in an anaerobic envi-
ronment for 4 days. Artificial saliva was replaced daily.
Heat-killed P. gingivalis was obtained by incubating a
1 9 108 CFU/ml suspension of bacteria in PBS at 56 C
for 30 min.
OKF6/TERT-2 cell culture
OKF6/TERT-2 oral keratinocytes were a gift from the
Rheinwald Laboratory (Brigham and Women’s Hospital,
Boston, USA). OKF6/TERT-2 cells were cultured in
keratinocyte serum-free medium (KSFM) supplemented
with 25 lg/ml bovine pituitary extract, 0.2 ng/ml epider-
mal growth factor (Life Technologies), 2 mM L-glutamine,
100 IU/ml penicillin, 100 mg/ml streptomycin and 0.4 lM
calcium chloride (Sigma-Aldrich, UK) at 37 C with 5 %
CO2. The growth media were changed at three-day inter-
vals and cells were passaged when they reached 70–80 %
confluence.
For in vitro experiments, 1 9 105 OKF6/TERT-2 cells
were seeded into 24-well plates. The plates were then
incubated at 37 C with 5 % CO2 overnight. The following
day, the media in each well were changed to defined
keratinocyte serum-free media (D-KSFM) (Invitrogen,
UK). To stimulate the cells, the Thermanox coverslips,
with the live P. gingivalis biofilms, were attached to Mil-
licell cell culture inserts (Millipore, UK) using Vaseline
and suspended above the cell monolayer. This was con-
ducted in the presence of varying pharmacological
concentrations (10, 100, 1,000 nM) of a commercially
available a7nAChR agonist, PHA-543613 hydrochloride
(HCl; Tocris, UK). For control purposes, cells were left
unstimulated or exposed to 1,000 nM PHA-543613 HCl in
the absence of biofilm. To confirm the specific role of
a7nAChR, experiments were repeated in which 10 nM of
a7nAChR antagonist, a-bungarotoxin (Tocris), was added
to cells 30 min prior to PHA-543613 HCl. The plates were
then incubated at 37 C with 5 % CO2 for 4 or 24 h. At
each time point, the bathing supernatant was harvested for
analysis by ELISA and the cell monolayer lysed with RLT
buffer (Qiagen) for RNA isolation.
SYBR green real-time PCR
To measure changes in IL-8 mRNA expression, mRNA
was extracted from cell monolayers using an RNeasy
mini kit (Qiagen). RNA was reverse transcribed to cDNA
as described previously. IL-8 mRNA was then measured
using SYBR green real-time PCR technology with the
following primers—GAPDH: Forward: CAAGGCT
GAGAACGGAAG and Reverse: GGTGGTGAAGA
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CGCCAGT; IL-8: Forward: CAGAGACAGCAGAG
CACACAA and Reverse: TTAGCACTCCTTGGCAA
AAC. Real-time PCR was performed on a MX3000PTM
real-time PCR machine (Stratagene). Data were analysed
using MxPro-MX3000P software, version 4.10 (Strata-
gene). Relative expression of IL-8 mRNA was calculated
using the 2-DDCT method for graphical purposes; however,
the 2-DCT values were used for statistical analysis.
IL-8 ELISA
Measurement of IL-8 release into bathing supernatants
was performed using the human IL-8 Cytoset (Invitro-
gen) according to the manufacturer’s recommendations.
Briefly, monoclonal antibodies specific for IL-8 were
pre-coated onto a MaxiSorp F96 Immunoplate (NUNC,
Denmark) and incubated overnight at 4 C. The follow-
ing day, the plate was washed with PBS-0.05 % Tween
20 and 100 ll of standards and samples added to each
well along with 50 ll of working detection antibody.
The plate was incubated for 2 h at room temperature
with continual shaking and then washed 5 times before
the addition of 100 ll of streptavidin-HRP. The plate
was incubated for a further 30 min, washed and the
reaction developed with 100 ll of TMB (3,30,5,50-tetra-
methylbenzidine) (KPL, USA). The intensity of the
colour was read at both 650 and 450 nm using a Fluostar
Omega microplate reader (BMG Labtech, Germany).
Data analysis was performed using BMG Analysis
Software (BMG Labtech).
GeneBLAzer M3 CHO-K1-bla cell reporter assay
To measure ACh release, 1 9 105 OKF6/TERT-2 cells
were seeded into 24-well plates and incubated at 37 C
with 5 % CO2 overnight. The following day, the media
was replaced with media containing PHA-543613 HCl
(10, 100 and 1,000 nM) or P. gingivalis LPS (0.1 and
1 lg/ml) and the cells were incubated for 4 h. Media
were then changed to media containing 0.5 mM physo-
stigmine hemisulphate (an ACh esterase inhibitor) and
incubated for a further 10 min before harvesting the
bathing supernatants. ACh release into supernatants was
determined using a GeneBLAzer M3 CHO-K1-bla cell
reporter assay (Invitrogen) as described previously [32].
The experiments were performed in duplicate on three
separate occasions. The average response for each
experiment was then determined along with the mean of
all three experiments. These values were then used to
standardise the data set. The data presented show the
total ACh (nM) released during a 10-min period.
Fast-activated cell-based ELISA (FACETM) NF-jB p65
profiler
The effect of PHA-543613 HCl on the activation of NF-
jB was investigated using the FACETM NF-jB p65
profiler (Active Motif, UK). OKF6/TERT-2 cells were
seeded into 96-well plates at a density of 1 9 105 cells/
well and left to adhere overnight at 37 C with 5 %
CO2. The following day, cells were stimulated for
30 min with either 1,000 nM PHA-543613 HCl alone,
dead (heat-killed) P. gingivalis alone (MOI = 200) or in
the presence of varying concentrations (10, 100,
1,000 nM) of PHA-543613 HCl. Supernatants were then
discarded and the cells fixed with 4 % formaldehyde.
Quenching was then performed using 1 % H2O2 (v/v)
and 0.1 % azide (v/v) in PBS. After quenching, cells
were incubated with antibody-blocking buffer prior to the
addition of 40 ll of primary antibody—anti-phospho-
NFjB p65 (S468), anti-phospho-NFjB p65 (S536) or
anti-total NFjB p65. For negative control wells, antibody
dilution buffer only was added. Cells were then incu-
bated overnight at 4 C. The following day, the cells
were washed and incubated with HRP-conjugated sec-
ondary antibody and then exposed to developing solution
for 15 min. The absorbance of each well was then
measured at 570 nm with a reference wavelength of
655 nm using a Fluostar Omega microplate reader
(BMG Labtech). To correct the data for cell numbers,
the cells were washed and a crystal violet assay per-
formed. All data analysis was performed using BMG
Analysis Software (BMG Labtech). The experiment was
performed in duplicate on three separate occasions.
The percentage of the total NF-jB p65 subunit which
was phosphorylated at serine 468 or serine 536 was then
calculated in accordance with the manufacturer’s
instructions. The percentage data were subjected to
angular transformation to parametric data for graphical
representation and statistical analysis.
To confirm that changes in NF-jB p65 subunit phos-
phorylation state corresponded with modulation of IL-8
expression, simultaneous experiments were performed in
which replicate cultures in 96-well plates were exposed to
the same conditions as described above. The supernatants
were harvested after 4 h and IL-8 release investigated by
ELISA.
STAT-3 in-cell ELISA
The effect of PHA-543613 HCl on the activation of
STAT-3 signalling was investigated using the STAT-3
in-cell ELISA kit (Thermo Scientific, UK). OKF6/TERT-
2 cells were seeded into 96-well plates at a density of
1 9 104 cells/well and left to adhere overnight at 37 C
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with 5 % CO2. The following day, cells were stimulated
for 30 min with either 1,000 nM PHA-543613 HCl
alone, dead P. gingivalis alone (MOI = 200) or dead P.
gingivalis in the presence of varying concentrations (10,
100 and 1,000 nM) of PHA-543613 HCl. Supernatants
were then discarded and the cells fixed with 4 % form-
aldehyde. The cells were then permeabilised and
quenching performed with 1 % H2O2 (v/v) and 0.1 %
azide (v/v). After quenching, cells were incubated with
antibody-blocking buffer prior to the addition of 50 ll of
anti-phospho-STAT3 (Y705) or anti-total STAT3 primary
antibody. For negative control wells, antibody dilution
buffer only was added. Cells were then incubated over-
night at 4 C. The following day, the cells were washed
and incubated with a secondary HRP-conjugated anti-
body and then exposed to developing solution for
2–20 min until the desired blue colour was achieved.
The development reaction was then stopped by addition
of a stop solution. The absorbance of each well was then
measured at 450 nm with a reference wavelength of
655 nm using a Fluostar Omega microplate reader
(BMG Labtech). To correct the data for cell numbers,
the cells were washed and a crystal violet assay per-
formed. All data analysis was performed using BMG
Analysis Software (BMG Labtech). The experiment was
performed in duplicate on three separate occasions.
The percentage of the total STAT3 which was phos-
phorylated at tyrosine 705 was then calculated in
accordance with the manufacturer’s instructions.
The percentage data were subjected to angular transfor-
mation to parametric data for graphical representation
and statistical analysis.
To confirm that changes in STAT-3 phosphorylation
state corresponded with modulation of IL-8 expression,
simultaneous experiments were performed in which repli-
cate cultures in 96-well plates were exposed to the same
conditions as described above. The supernatants were
harvested after 4 h and IL-8 release investigated by ELISA.
Statistical analysis
Statistical analysis was performed using SPSS (IBM,
Chicago, USA). The type 1 error alpha for a 2-sided
probability was set at 0.05.
Tissue real-time PCR data and real-time PCR data
investigating changes in IL-8 mRNA expression in cultured
OKF6/TERT-2 cells were analysed by performing Le-
vene’s test on the variance of the natural log-transformed
2-DCT values followed by an independent t test to compare
two means (significance was set at P \ 0.05).
Statistical analysis of ELISA data was performed by log
transformation followed by ANOVA with a post hoc
Bonferroni correction.
The standardised GeneBLAzer data were subjected to
Levene’s test of homoscedasticity. Since the variance of all
the data was not significantly different, the statistical dif-
ference between mean values for treatments and controls in
each experiment was determined by linear ANOVA and a
post hoc least significant difference test with Holm-Bon-
ferroni (H–B) correction (significance was set at
P = \0.05/H–B correction factor).
The angular-transformed NF-jB or STAT-3 data were
subjected to Levene’s test of homoscedasticity. Again,
since the variance of all the data was not significantly
different, the statistical difference between mean values for
treatments and controls in each experiment was determined
by linear ANOVA and a post hoc least significant differ-
ence test with H–B correction (significance was set at
P = \0.05/H–B correction factor).
Results
a7nAChR mRNA expression is elevated in diseased
periodontal tissues
The mean level of a7nAChR mRNA expression was
elevated in the tissue of 17 patients with periodontal
disease when compared with 9 control tissue samples
(periodontal disease 2-DCT = 0.46 vs healthy 2-DCT = 0.24,
P = 0.017, Fig. 1).
Fig. 1 a7nAChR mRNA expression is upregulated in the tissue of
patients with periodontal disease. RNA was isolated from tissue
samples from healthy patients and those with periodontal disease and
analysed for a7nAChR mRNA expression by real-time PCR.
a7nAChR mRNA expression was normalised against a housekeeping
gene, RNA Polymerase II. The data presented represent the mean with
95 % confidence intervals of the normalised a7nAChR mRNA
expression for the two cohorts calculated by the 2-DCT method.
Statistical analysis involved Levene’s test of homoscedasticity on the
natural log-transformed 2-DCT values followed by an independent
t test to compare two means (*P \ 0.05)
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a7nAChR agonist PHA-543613 HCl inhibits
P. gingivalis-induced expression of IL-8 by
OKF6/TERT-2 cells
Stimulation of OKF6/TERT-2 cells with a P. gingivalis
biofilm for 4 h induced significant release of IL-8 in control
unstimulated cells from 28.79 ± 11.68 pg/ml to
380.95 ± 22.03 pg/ml (P \ 0.001) (Fig. 2a). P. gingivalis-
induced IL-8 release was inhibited by PHA-543613 HCl
(10 nM = 217.01 ± 68.72 pg/ml, P = 0.043; 100 nM =
127.71 ± 58.83 pg/ml, P = 0.014 and 1,000 nM =
94.98 ± 29.65 pg/ml, P = 0.012) (Fig. 2a). Similar effects
were seen at 24 h, with P. gingivalis inducing significant
release of IL-8 in control unstimulated cells from
118.67 ± 61.12 pg/ml to 1,190.67 ± 209.57 pg/ml (P =
0.004) (Fig. 2a). Again, this induction of IL-8 release was
inhibited by PHA-543613 HCl (10 nM = 710.88 ±
222.67 pg/ml, P = 0.046; 100 nM = 129.85 ± 15.69 pg/
ml, P = 0.013 and 1,000 nM = 76.10 ± 10.92 pg/ml,
P = 0.011) (Fig. 2a).
The inhibition of IL-8 production was mediated at the
transcriptional level (Fig. 2b). IL-8 mRNA expression
increased 7.90 ± 3.65-fold after 4 h stimulation with P.
gingivalis (P = 0.032). IL-8 mRNA expression levels were
not significantly different when cells were pre-stimulated
with 10 and 100 nM PHA-543613 HCl. However, a sig-
nificant reduction in IL-8 mRNA was observed after 4 h
when cells were pre-stimulated with 1,000 nM PHA-
543613 HCl (1.28 ± 1.28-fold, P = 0.011). At 24 h, P.
gingivalis increased IL-8 mRNA expression 12.11 ± 3.86-
fold (P = 0.002). However, in the presence of PHA-
543613 HCl, IL-8 mRNA levels were significantly lower
with all concentrations investigated (10 nM = 4.66
± 2.56-fold, P = 0.041; 100 nM = 1.76 ± 3.90-fold,
P = 0.014 and 1,000 nM = 0.84 ± 1.28-fold, P = 0.011)
(Fig. 2b).
The reduction in IL-8 expression was unrelated to cell
viability as determined by a lactate dehydrogenase activity
assay (data not shown).
To confirm that the effects of PHA-543613 HCl were
specifically mediated by a7nAChR, experiments were
repeated using a specific a7nAChR antagonist, a-bunga-
rotoxin. The P. gingivalis biofilm induced significant IL-8
release from OKF6/TERT-2 cells at 4 h (control =
47.74 ± 12.27 pg/ml and biofilm = 221.86 ± 50.57 pg/
ml; P \ 0.001) and 24 h (control = 85.84 ± 12.03 pg/ml
and biofilm = 1,088.80 ± 185.96 pg/ml; P \ 0.001). In
addition, the P. gingivalis biofilm-induced IL-8 release was
again inhibited by 1,000 nM PHA-543613 HCl at 4 h
(biofilm = 221.86 ± 50.57 pg/ml and biofilm ? 1,000
nM PHA-543613 HCl = 35.42 ± 11.59 pg/ml; P \ 0.05)
and 24 h (biofilm = 1,088.80 ± 185.96 pg/ml and bio-
film ? 1,000 nM PHA-543613 HCl = 70.80 ± 11.59 pg/
ml; P \ 0.05) (Fig. 2c). a-Bungarotoxin alone or in com-
bination with PHA-543613 HCl had no effect on IL-8
release from OKF6/TERT-2 cells (data not shown). In
addition, a-bungarotoxin had no effect on P. gingivalis
biofilm-induced IL-8 release from OKF6/TERT-2 cells
(data not shown). However, a-bungarotoxin abolished
PHA-543613 HCl-mediated downregulation of P. gingi-
valis-induced IL-8 release from OKF6/TERT-2 cells at 4 h
(biofilm = 221.86 ± 50.57 pg/ml and biofilm ? 1,000
nM PHA-543613 HCl ? 10 nM a-bungarotoxin =
188.19 ± 54.29 pg/ml; P [ 0.05) and at 24 h (bio-
film = 1,088.80 ± 185.96 pg/ml and biofilm ? 1,000 nM
PHA-543613 HCl ? 10 nM a-bungarotoxin = 1,018.33
± 192.72 pg/ml; P [ 0.05) (Fig. 2c).
P. gingivalis LPS and PHA-543613 HCl modulate
the release of ACh from OKF6/TERT-2 cells
OKF6/TERT-2 cells were either left unstimulated (basal)
or stimulated with P. gingivalis LPS or PHA-543613 HCl
for 4 h. A 10-min snapshot of ACh release into bathing
media was then determined using the GeneBLAzer M3
CHO-K1-bla cell reporter assay. The basal release level of
ACh from OKF6/TERT-2 cells was 0.66 ± 0.09 nM over
a period of 10 min (Fig. 3). No significant change in basal
ACh release was observed with 10 and 100 nM PHA-
543613 HCl or 0.1 lg/ml P. gingivalis LPS. ACh release
was significantly downregulated from basal levels in
response to 1,000 nM PHA-543613 HCl to
0.37 ± 0.13 nM over a period of 10 min (P = 0.031). In
contrast, there was a significant increase in ACh release
from basal levels by cells stimulated with 1 lg/ml P.
gingivalis LPS to 0.83 ± 0.91 nM over a period of 10 min
(P = 0.042) (Fig. 3).
PHA-543613 HCl regulates the expression of IL-8
in P. gingivalis-stimulated OKF6/TERT-2 cells
by inhibiting phosphorylation of the NF-jB p65 subunit
Exposure of OKF6/TERT-2 cells to dead P. gingivalis or
PHA-543613 HCl for 30 min had no significant effect on
total NF-jB p65 subunit levels (data not shown). Stimu-
lation of OKF6/TERT-2 cells with dead P. gingivalis
caused significantly elevated phosphorylation of the NF-jB
p65 subunit at serine 468 from 32.51 ± 4.92 (29 %) in
control cells to 39.51 ± 4.92 (40 %) in stimulated cells
(P = 0.016) (Fig. 4a). In addition, stimulation also caused
significantly elevated phosphorylation of the NF-jB p65
subunit at serine 536 from 26.56 ± 6.02 (23 %) in control
cells to 36.62 ± 6.38 (31 %) in stimulated cells
(P = 0.013) (Fig. 4b). There was a significant decrease in
P. gingivalis-induced NF-jB activation when conducted in
the presence of 1,000 nM PHA-543613 HCl.
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Phosphorylation of the NF-jB p65 subunit at serine 468
was reduced from 39.51 ± 4.92 (40 %) to 27.92 ± 8.52
(23 %) (P = 0.011) (Fig. 4a) and serine 536 from
36.62 ± 6.38 (31 %) to 21.04 ± 8.99 (22 %)
(P = 0.014) (Fig. 4b). Linear ANOVA analysis showed
there was a dose-dependent reduction in phosphorylation of
serine 468 (P \ 0.05) and serine 536 (P \ 0.05) in the
presence of PHA-543613 HCl but only the 1,000 nM
Fig. 2 PHA-543613 HCl
inhibits P. gingivalis-induced
expression of IL-8 by OKF6/
TERT-2 oral keratinocytes
through specific activation of
a7nAChR. P. gingivalis-
induced release of IL-8 by
OKF6/TERT-2 oral
keratinocytes was inhibited by
the a7AChR agonist PHA-
543613 HCl (a). The inhibition
of release by the a7AChR
agonist PHA-543613 HCl was
mediated at the transcriptional
level (b). The specific role of
a7AChR in mediating the
inhibition of P. gingivalis-
induced expression and release
of IL-8 was demonstrated using
the specific antagonist, a-
bungarotoxin (c). IL-8 release
into bathing supernatants was
determined by ELISA and
changes in IL-8 mRNA
expression by real-time PCR.
ELISA data are presented as the
mean IL-8 release with standard
deviation (SD) and are derived
from duplicate wells of 3
independent experiments
(n = 3). Statistical analysis of
ELISA data was performed by
log transforming the data
followed by ANOVA with a
post hoc Bonferroni corrected
t test (*P \ 0.05). Real-time
PCR data are presented as the
fold induction change (±SD) in
IL-8 mRNA expression in
relation to the unstimulated
control (2-DDCT). The data are
derived from duplicate wells of
3 independent experiments
(n = 3). Statistical analysis of
real-time PCR data was
performed by Levene’s test of
homoscedasticity on the natural
log-transformed 2-DCT values
followed by an independent
t test to compare two means
(*P \ 0.05)
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concentration reached statistical significance in both cases.
Analysis of IL-8 release into bathing supernatants from
simultaneous cultures showed that the changes in IL-8
release correlated with changes in the phosphorylation state
of the NF-jB p65 subunit (data not shown).
PHA-543613 HCl regulates the expression of IL-8
in P. gingivalis-stimulated OKF6/TERT-2 cells
by maintaining phosphorylation of STAT-3
Exposure of OKF6/TERT-2 cells to dead P. gingivalis or
PHA-543613 HCl had no significant effect on total STAT-
3 levels (data not shown). Stimulation of OKF6/TERT-2
cells with dead P. gingivalis caused significantly
(P = 0.022) decreased phosphorylation of STAT-3 at
tyrosine 705 from 39.02 ± 0.01 (40 %) in control cells to
21.77 ± 5.74 (14 %) in stimulated cells (P = 0.011)
(Fig. 5). In comparison to P. gingivalis-stimulated cells
alone (21.77 ± 5.74; 14 %), levels of STAT-3 phos-
phorylated at tyrosine 705 were significantly higher in cells
stimulated with P. gingivalis in the presence of 100 nM
(37.42 ± 5.12, 38 %; P = 0.024) and 1,000 nM
(39.07 ± 8.67, 40 %, P = 0.013) PHA-543613 HCl
(Fig. 5). Linear ANOVA analysis also showed there was a
dose-dependent increase in levels of STAT-3 phosphory-
lated at tyrosine 705 in the presence of PHA-543613 HCl
(P \ 0.05) but only the 100 and 1,000 nM concentrations
reached statistical significance. Analysis of IL-8 release
into bathing supernatants from simultaneous cultures
showed that changes in IL-8 release correlated with chan-
ges in the phosphorylation state of STAT-3 (data not
shown).
Discussion
a7nAChR signalling has anti-inflammatory effects on
epithelial cells [14–17, 23]. In agreement, this study
showed a7nAChR signalling inhibits P. gingivalis-induced
expression of IL-8 by oral keratinocytes. a7nAChR exerts
its anti-inflammatory effects in monocytes through inhib-
ited NF-jB activation [18]. This study suggests that
a7nAChR mediates similar effects in epithelial cells. NF-
jB exists in cells in an inactivated form and IL-8 gene
transcription is reliant on NF-jB activation, which occurs
through phosphorylation of the NF-jB p65 subunit and
degradation of the inhibitory protein IjB [33, 34]. In this
study, a7nAChR activation inhibited P. gingivalis LPS-
induced phosphorylation of the NF-jB p65 subunit at
serine 468 and 536 in oral keratinocytes. Phosphorylation
of the NF-jB p65 subunit at serine 536 has been shown to
play a role in NF-jB activation [35, 36]. In contrast,
phosphorylation at serine 468 has been shown to play an
important role in NF-jB ubiquitination and degradation
[37]. Despite their opposing functions, phosphorylation at
serine 536 and 468 occurs simultaneously [36]. Therefore,
NF-jB activation and regulation may go hand in hand.
Indeed, phosphorylation of serine 468 is suggested to be a
Fig. 3 P. gingivalis LPS and PHA-543613 HCl modulate the release
of ACh from OKF6/TERT-2 cells. The concentration of ACh in cell
culture supernatants was determined using the GeneBLAzer M3
CHO-K1-bla cell reporter assay. The data represent the total
concentration of ACh (with SD) in supernatants after a 10-min
incubation period with a correction for cell number. The data are
derived from duplicate wells of 3 independent experiments (n = 3).
The data were standardised and statistical analysis performed by
ANOVA and a post hoc Holm-Bonferroni (H–B) corrected least
significant difference test (*P \ 0.05/H–B)
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hallmark of constitutively activated NF-jB in chronic
inflammatory diseases [38]. Phosphorylation of serine 536
of the NF-jB p65 subunit has been demonstrated to be
important in transcription of the IL-8 gene [39]. However,
at present, the role that phosphorylation of serine 468 plays
in IL-8 transcription is unknown.
Previous studies have demonstrated a role for STAT-3
in suppression of IL-8 transcription [40]. In macrophages,
the anti-inflammatory effects of a7nAChR signalling are in
part driven by activation of STAT-3 [19]. This study
demonstrates that a similar phenomenon occurs in epithe-
lial cells. Indeed, PHA-543613 HCl inhibited P. gingivalis
LPS-induced expression of IL-8 by oral keratinocytes
through maintained STAT-3 tyrosine 705 phosphorylation.
Phosphorylation of tyrosine 705 is reported to induce
STAT-3 activation [41], which in turn causes dimerisation
and binding to target genes [42] as well as promoting
suppressor of cytokine signalling 3 (SOCS-3) activation
[43, 44]. In macrophages, a7nAChR exerts its anti-
inflammatory effects by direct activation of STAT-3 and
not through increased SOCS-3 activity [19]. In this study,
activation of SOCS-3 was not measured. Therefore,
although it can be concluded that direct activation of
STAT-3 is responsible for a7nAChR-mediated inhibition
of IL-8 expression by oral keratinocytes, it is still unknown
whether this occurs through SOCS-3-dependent or -inde-
pendent mechanisms.
In this study, stimulation of oral keratinocytes with P.
gingivalis LPS induced a significant decrease in the per-
centage of STAT-3 phosphorylated at tyrosine 705. This
decrease in phosphorylation coincided with increased IL-8
expression (data not shown). In contrast, studies using live
P. gingivalis have shown it to induce an increase in
phosphorylation of STAT-3 tyrosine 705 in gingival epi-
thelial cells [45, 46]. This increased activation of STAT-3
is suggested to be related to the process of internalisation
Fig. 4 The a7AChR agonist
PHA-543613 HCl inhibits P.
gingivalis-induced
phosphorylation of the NF-jB
p65 subunit at serine 536 and
468. The percentage of the NF-
jB p65 subunit phosphorylated
at serine residues 536 (a) and
468 (b) was calculated. The data
represent the mean angular-
transformed percentage of NF-
jB p65 subunit phosphorylated
at each residue with the SD. The
data are derived from duplicate
wells of 3 independent
experiments (n = 3). Statistical
analysis was performed by
ANOVA and a post hoc Holm-
Bonferroni (H–B) corrected
least significant difference test
(*P \ 0.05/H–B)
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and intracellular adaptation [45]. Therefore, the differential
finding in our study may be related to the use of P. gin-
givalis LPS as a stimulator. Indeed, different P. gingivalis
antigens have in fact been shown to have differential
effects on STAT-3 phosphorylation in monocytes. Fur-
thermore, in agreement with the data presented in this
study, P. gingivalis LPS has been found to downregulate
STAT-3 activation [47].
Oral keratinocytes can synthesise and release ACh [21]
and evidence suggests that levels are elevated in oral
pathologies [3]. The mechanisms controlling release of
ACh from non-neuronal cells are at present poorly under-
stood. Placental models have demonstrated a role for
organic cation transporter 3 (OCT-3). Pharmacological
evidence suggests that oral epithelial cells express OCTs
[48]. Furthermore, data from our laboratory suggest oral
keratinocytes express OCT-3 mRNA (data not shown).
However, at present, the exact mechanisms by which oral
keratinocytes mediate the synthesis and release of ACh
remain unknown. The data show that P. gingivalis LPS can
trigger an increase in ACh release from oral keratinocytes.
In contrast, agonist-induced a7nAChR signalling triggers a
decrease in the release of ACh. Although these findings are
in the preliminary stages, it is interesting to speculate that
during inflammation the release of ACh from oral kerati-
nocytes is tightly regulated. This regulation may be
important in ensuring the immune response is appropriate
for the perceived threat. Furthermore, as oral keratinocytes,
fibroblasts and numerous immune cells express a7nAChR,
a complex network of autocrine and paracrine non-neuro-
nal signalling mechanisms can be hypothesised to be
operating within the periodontium that may play a role in
periodontal disease pathogenesis. Indeed, this study shows
that a7nAChR mRNA levels are elevated in the tissue of
patients with periodontal disease. Furthermore, our data
suggest that the elevated a7nAChR mRNA expression in
diseased periodontal tissue is due to an increased influx of
a7nAChR? immune cells (data not shown). The precise
a7nAChR? immune cell subsets in diseased periodontal
tissue and their role in disease pathogenesis are currently a
matter for further investigation.
The results presented here indicate that non-neuronal
ACh and a7nAChR may play a role in regulating patho-
gen-induced immune response at epithelial surfaces. They
may also play a role in the pathogenesis of epithelial
inflammatory pathologies such as periodontal disease.
However, further research is required to investigate the
physiological and immunoregulatory functions of non-
neuronal ACh/a7nAChR-mediated signalling mechanisms
within periodontal tissues.
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